Drug
Glatiramer clinical trials
Also written Copaxone.
- studies test it
- 38
- open now
- 0
- in phase 3
- 14
- first study started
- 1991
How studies write it
Studies that test it under each name
Studies by the year they started
38 studies that test it; most in 2006 (5)
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1994 | 1 |
| 2003 | 4 |
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2019 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 12
- Phase 3
- 14
- Phase 4
- 9
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 18
Teva Branded Pharmaceutical Products R&D, Inc. (11) · Teva Neuroscience, Inc. (2) · Sanofi (2) · Sheba Medical Center (2) · The Cleveland Clinic (1) · University of Kansas Medical Center (1) · Hadassah Medical Organization (1) · Teva Pharmaceutical Industries, Ltd. (1)
Often tested with
Tested in the same studies.
Interferon beta-1a (3) · Natalizumab (2) · Methylprednisolone (2) · Interferon beta-1b (1) · Rituximab (1) · Teriflunomide (1) · Acetylcysteine (1) · Alemtuzumab (1)
Studies
Open first, then newest update. How each study uses glatiramer is read from its arms, and is right about nine times in ten.
Testing it · 38
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSActive, not recruitingPhase 4The Cleveland ClinicNCT03535298Written as Escalation Therapies Group
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMTTerminatedPhase 3Genzyme, a Sanofi CompanyNCT03368664Written as Glatiramer acetate
- Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart FailureCompletedPhase 2Hadassah Medical OrganizationNCT06003972Written as Copaxone
- A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible TumorsActive, not recruitingPhase 1University of Kansas Medical CenterNCT03982212Written as Copaxone
- Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2Teva Pharmaceutical Industries, Ltd.NCT00326625Written as 40 mg glatiramer acetate
- Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®CompletedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT02499900Written as Copaxone®
- A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to PlaceboCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01067521Written as Glatiramer acetate (GA)
- Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRICompletedPhase 4University of Medicine and Dentistry of New JerseyNCT00176592Written as Copaxone
- Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple SclerosisCompletedPhase 3BiocadNCT02753088Written as BCD-063
- Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)CompletedNot applicableUniversity at BuffaloNCT00937157Written as Copaxone
- Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and EffectivenessCompletedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT00203021Written as Glatiramer acetate
- Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis PatientsCompletedPhase 2/3Isfahan University of Medical SciencesNCT03315923Written as Glatiramer Acetate
- Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)CompletedPhase 2Montefiore Medical CenterNCT02153723Written as Glatiramer Acetate
- High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple SclerosisWithdrawnPhase 2Johns Hopkins UniversityNCT00939549Written as Cyclophosphamide/Glatiramer acetate
- A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)CompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT00856635Written as Glatiramer Acetate
- A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®CompletedPhase 4Teva Neuroscience, Inc.NCT00239993Written as glatiramer acetate
- Efficacy and Safety of GTR in Comparison to Copaxone®CompletedPhase 3Synthon BVNCT01489254Written as Glatiramer Acetate (GTR)
- Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRxCompletedPhase 3Fred LublinNCT00211887Written as glatiramer acetate
- An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01578785Written as Glatiramer Acetate
- An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett SyndromeStatus unknownPhase 1Sheba Medical CenterNCT02023424Written as Glatiramer Acetate (Copaxone®)
See all 38 studies that test glatiramer →
Given in every arm · 6 — glatiramer is usual care beside what is tested
- Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)WithdrawnPhase 2BiogenNCT04079088Written as Glatiramer acetate
- Comparison of Rituximab Induction Therapy Followed by Glatiramer AcetateCompletedPhase 2University of Colorado, DenverNCT01569451Written as Glatiramer Acetate
- Treatment of Multiple Sclerosis With Copaxone and AlbuterolCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00039988Written as Glatiramer acetate
- A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)CompletedPhase 2University of California, Los AngelesNCT00451204Written as Copaxone
- Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer AcetateTerminatedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT00203047Written as Glatiramer Acetate
- Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple SclerosisCompletedPhase 2SanofiNCT00475865Written as Glatiramer Acetate (GA)
As the comparator · 10 — what is tested is compared with glatiramer
- MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus CopaxoneTerminatedPhase 3Novartis PharmaceuticalsNCT01633112Written as glatiramer acetate
- Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple SclerosisCompletedPhase 4EMD SeronoNCT00078338Written as Copaxone®
- Safety of New Formulation of Glatiramer AcetateCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT00947752Written as Glatiramer Acetate
- Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)TerminatedPhase 2EMD SeronoNCT01963611Written as Copaxone 20 mg
- Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple SclerosisCompletedPhase 3BiogenNCT00451451Written as Glatiramer Acetate
- Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisTerminatedPhase 3BiogenNCT01058005Written as glatiramer acetate
- Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)CompletedPhase 4Novartis PharmaceuticalsNCT01534182Written as Glatiramer acetate (GA)
- Safety and Efficacy Study of Copaxone Administered in Combination With MinocyclineCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT00203112Written as glatiramer acetate with minocycline
- A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.CompletedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT00240032Written as glatiramer acetate injection with oral cetirizine hydrochloride
- BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) PatientsCompletedPhase 3BayerNCT00099502Written as Copaxone
Codes
What other systems call glatiramer · ClinicalTrials.gg INT006532
- MeSH (NLM) D000068717Glatiramer AcetateConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) U782C039QPGLATIRAMERConfirmed FDA, NLM
- RxNorm 214582One source FDA
- NCI Thesaurus C87680GlatiramerOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068717 | Glatiramer Acetate | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | U782C039QP | GLATIRAMER | Confirmed FDA, NLM |
| RxNorm | 214582 | — | One source FDA |
| NCI Thesaurus | C87680 | Glatiramer | One source FDA |
Also registered as glatiramer acetate (UNII 5M691HL4BO · RxNorm 84375).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.